Kenneth Marek

30.9k total citations · 3 hit papers
189 papers, 13.5k citations indexed

About

Kenneth Marek is a scholar working on Neurology, Cellular and Molecular Neuroscience and Physiology. According to data from OpenAlex, Kenneth Marek has authored 189 papers receiving a total of 13.5k indexed citations (citations by other indexed papers that have themselves been cited), including 115 papers in Neurology, 44 papers in Cellular and Molecular Neuroscience and 29 papers in Physiology. Recurrent topics in Kenneth Marek's work include Parkinson's Disease Mechanisms and Treatments (103 papers), Neurological disorders and treatments (82 papers) and Alzheimer's disease research and treatments (23 papers). Kenneth Marek is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (103 papers), Neurological disorders and treatments (82 papers) and Alzheimer's disease research and treatments (23 papers). Kenneth Marek collaborates with scholars based in United States, Germany and Canada. Kenneth Marek's co-authors include John Seibyl, Daniela Berg, Werner Poewe, Matthew Stern, Anthony E. Lang, Thomas Gasser, C. Warren Olanow, Wolfgang H. Oertel, Ronald B. Postuma and Günther Deuschl and has published in prestigious journals such as Science, New England Journal of Medicine and Nature Medicine.

In The Last Decade

Kenneth Marek

184 papers receiving 13.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MDS clinical diagnostic criteria for Parkinson's disease

2015 4.8k citations Ronald B. Postuma, Daniela Berg et al. Movement Disorders profile →
MDS research criteria for prodromal Parkinson's disease

2015 876 citations Daniela Berg, Ronald B. Postuma et al. Movement Disorders profile →
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease

2024 56 citations Gennaro Pagano, Tanya Simuni et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kenneth Marek United States	52	9.9k	3.5k	2.0k	1.8k	1.8k	189	13.5k
Piu Chan China	51	7.6k 0.8×	2.7k 0.8×	2.5k 1.2×	2.2k 1.2×	2.3k 1.3×	189	13.5k
S. E. Daniel United Kingdom	29	11.0k 1.1×	3.4k 1.0×	2.0k 1.0×	1.6k 0.9×	1.8k 1.0×	44	13.7k
Reinhard Dengler Germany	59	6.8k 0.7×	2.8k 0.8×	1.5k 0.7×	2.1k 1.2×	2.0k 1.1×	378	12.4k
Andrew Siderowf United States	60	10.5k 1.1×	2.6k 0.8×	2.4k 1.2×	2.5k 1.4×	1.0k 0.6×	185	14.5k
Paolo Barone Italy	71	12.3k 1.2×	4.2k 1.2×	1.3k 0.7×	3.4k 1.9×	2.0k 1.1×	418	17.6k
Howard I. Hurtig United States	63	9.5k 1.0×	3.0k 0.9×	3.6k 1.8×	2.5k 1.4×	1.5k 0.8×	140	13.9k
Jan Booij Netherlands	62	5.9k 0.6×	4.4k 1.3×	1.5k 0.7×	2.0k 1.1×	1.4k 0.8×	349	13.6k
Ernst N.H. Jansen Steur Netherlands	24	6.9k 0.7×	2.9k 0.8×	2.3k 1.1×	1.1k 0.6×	1.9k 1.1×	33	10.0k
Nicolaas I. Bohnen United States	57	5.3k 0.5×	2.3k 0.7×	1.7k 0.9×	2.2k 1.2×	1.1k 0.7×	189	10.4k
Matthew Stern United States	33	8.3k 0.8×	2.2k 0.6×	1.2k 0.6×	1.4k 0.8×	826 0.5×	68	10.3k

Countries citing papers authored by Kenneth Marek

Since Specialization

Citations

This map shows the geographic impact of Kenneth Marek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Marek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Marek more than expected).

Fields of papers citing papers by Kenneth Marek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Marek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Marek. The network helps show where Kenneth Marek may publish in the future.

Co-authorship network of co-authors of Kenneth Marek

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Marek. A scholar is included among the top collaborators of Kenneth Marek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Marek. Kenneth Marek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Coughlin, David G., Carly M. Farris, Yihua Ma, et al.. (2025). α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease. Neurology. 104(5). e210279–e210279. 9 indexed citations

Soto, Claudio, Brit Mollenhauer, Oskar Hansson, et al.. (2025). Toward a biological definition of neuronal and glial synucleinopathies. Nature Medicine. 31(2). 396–408. 5 indexed citations

Marek, Kenneth, David Russell, Luis Concha‐Marambio, et al.. (2025). Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional study. EBioMedicine. 112. 105567–105567. 4 indexed citations

Pagano, Gennaro, Annabelle Monnet, Benjamin Ribba, et al.. (2024). Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial. Nature Medicine. 30(12). 3669–3675. 14 indexed citations

Brumm, Michael C., Kerri A. Pierz, David-Erick Lafontant, et al.. (2023). Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older. Neurology. 100(16). e1691–e1701. 25 indexed citations

Chahine, Lana M., Kalpana Merchant, Andrew Siderowf, et al.. (2023). Proposal for a Biologic Staging System of Parkinson’s Disease. Journal of Parkinson s Disease. 13(3). 297–309. 45 indexed citations

Merchant, Kalpana, Tanya Simuni, Chelsea Caspell‐Garcia, et al.. (2023). LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts. npj Parkinson s Disease. 9(1). 30–30. 12 indexed citations

Brumm, Michael C., Andrew Siderowf, Tanya Simuni, et al.. (2023). Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression. Journal of Parkinson s Disease. 13(6). 899–916. 25 indexed citations

Brown, Ethan, David Alonso–Gutiérrez, Lana M. Chahine, et al.. (2022). Parkinson’s Progression Markers Initiative (PPMI) Online expands biomarker research in Parkinson’s disease (PD) (P9-11.006). Neurology. 98(18_supplement). 2 indexed citations

10.

Kaur, Rachneet, Sayed Hadi Hashemi, Hampton L. Leonard, et al.. (2022). Identification and prediction of Parkinson’s disease subtypes and progression using machine learning in two cohorts. npj Parkinson s Disease. 8(1). 172–172. 50 indexed citations

11.

Marek, Kenneth, Andrew Siderowf, Karl Kieburtz, et al.. (2020). PPMI 2.O New Science/New Cohorts - Transforming PPMI (2490). Neurology. 94(15_supplement). 4 indexed citations

12.

Seibyl, John, Danna Jennings, & Kenneth Marek. (2015). Assessment of Parkinson disease progression using 123- I I-Ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial (I11-5C). Neurology. 84(14_supplement). 1 indexed citations

13.

Postuma, Ronald B., Daniela Berg, Matthew Stern, et al.. (2015). MDS clinical diagnostic criteria for Parkinson's disease. Movement Disorders. 30(12). 1591–1601. 4841 indexed citations breakdown →

14.

Qamhawi, Zahi, David Towey, Bina Shah, et al.. (2015). Clinical correlates of raphe serotonergic dysfunction in early Parkinson’s disease. Brain. 138(10). 2964–2973. 161 indexed citations

15.

Berg, Daniela, Ronald B. Postuma, Bastiaan R. Bloem, et al.. (2014). Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Movement Disorders. 29(4). 454–462. 341 indexed citations

16.

Tamagnan, Gilles, Adriana Tavares, Olivier Barret, et al.. (2012). Brain distribution of BZM055, an analog of fingolimod (FTY720), in human. Multiple Sclerosis Journal. 18. 379–379. 10 indexed citations

17.

Barret, Olivier, David Thomae, David Alagille, et al.. (2012). First in vivo assessment of two PDE10 tracers [18F]MNI654 and [18F]MNI659. 53(1). 361–361. 9 indexed citations

18.

Seibyl, John, I. George Zubal, Danna Jennings, Kenneth Marek, & P. Murali Doraiswamy. (2011). Molecular PET imaging in multicenter Alzheimer’s therapeutic trials: current trends and implementation strategies. Expert Review of Neurotherapeutics. 11(12). 1783–1793. 4 indexed citations

19.

Redmond, D. Eugene, Richard J. Robbins, Frederick Naftolin, et al.. (1993). Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients.. PubMed. 71. 325–59. 13 indexed citations

20.

Redmond, D. Eugene, Robert H. Roth, Dennis D. Spencer, et al.. (1993). Neural Transplantation for Neurodegenerative Diseases: Past, Present, and Future^a. Annals of the New York Academy of Sciences. 695(1). 258–266. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact